Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts

David M. Atkinson, Michelle J. Clarke, Ann C. Mladek, Brett L. Carlson, David P. Trump, Mark S. Jacobson, Brad J. Kemp, Val Lowe, Jann N Sarkaria

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. 3′-18F-fluoro-3′-deoxy-fluorothymidine ( 18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. Methods. We tested whether 18F-FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. Results. Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18%, whereas placebo increased SUV by 1% (p = .005). One week of cetuximab in SCC1 reduced SUV by 62%, whereas placebo reduced SUV by 16% (p = .005). FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase-1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. Conclusions. 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR-inhibitors early in their treatment course.

Original languageEnglish (US)
Pages (from-to)790-799
Number of pages10
JournalHead and Neck
Volume30
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Heterografts
Squamous Cell Carcinoma
Epidermal Growth Factor Receptor
Positron-Emission Tomography
Placebos
Neoplasms
Therapeutics
Nucleosides
alovudine
thymidine kinase 1
Cetuximab
Erlotinib Hydrochloride

Keywords

  • Anti-EGFR inhibitor therapy
  • Cetuximab
  • Erlotinib
  • Fluorodeoxythymidine (FLT)
  • Squamous cell carcinoma xenografts

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Atkinson, D. M., Clarke, M. J., Mladek, A. C., Carlson, B. L., Trump, D. P., Jacobson, M. S., ... Sarkaria, J. N. (2008). Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts. Head and Neck, 30(6), 790-799. https://doi.org/10.1002/hed.20770

Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts. / Atkinson, David M.; Clarke, Michelle J.; Mladek, Ann C.; Carlson, Brett L.; Trump, David P.; Jacobson, Mark S.; Kemp, Brad J.; Lowe, Val; Sarkaria, Jann N.

In: Head and Neck, Vol. 30, No. 6, 06.2008, p. 790-799.

Research output: Contribution to journalArticle

Atkinson, DM, Clarke, MJ, Mladek, AC, Carlson, BL, Trump, DP, Jacobson, MS, Kemp, BJ, Lowe, V & Sarkaria, JN 2008, 'Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts', Head and Neck, vol. 30, no. 6, pp. 790-799. https://doi.org/10.1002/hed.20770
Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS et al. Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts. Head and Neck. 2008 Jun;30(6):790-799. https://doi.org/10.1002/hed.20770
Atkinson, David M. ; Clarke, Michelle J. ; Mladek, Ann C. ; Carlson, Brett L. ; Trump, David P. ; Jacobson, Mark S. ; Kemp, Brad J. ; Lowe, Val ; Sarkaria, Jann N. / Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts. In: Head and Neck. 2008 ; Vol. 30, No. 6. pp. 790-799.
@article{86cc5a8a916a4c6d8032bbfb4b012d75,
title = "Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts",
abstract = "Background. 3′-18F-fluoro-3′-deoxy-fluorothymidine ( 18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. Methods. We tested whether 18F-FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. Results. Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18{\%}, whereas placebo increased SUV by 1{\%} (p = .005). One week of cetuximab in SCC1 reduced SUV by 62{\%}, whereas placebo reduced SUV by 16{\%} (p = .005). FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase-1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. Conclusions. 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR-inhibitors early in their treatment course.",
keywords = "Anti-EGFR inhibitor therapy, Cetuximab, Erlotinib, Fluorodeoxythymidine (FLT), Squamous cell carcinoma xenografts",
author = "Atkinson, {David M.} and Clarke, {Michelle J.} and Mladek, {Ann C.} and Carlson, {Brett L.} and Trump, {David P.} and Jacobson, {Mark S.} and Kemp, {Brad J.} and Val Lowe and Sarkaria, {Jann N}",
year = "2008",
month = "6",
doi = "10.1002/hed.20770",
language = "English (US)",
volume = "30",
pages = "790--799",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts

AU - Atkinson, David M.

AU - Clarke, Michelle J.

AU - Mladek, Ann C.

AU - Carlson, Brett L.

AU - Trump, David P.

AU - Jacobson, Mark S.

AU - Kemp, Brad J.

AU - Lowe, Val

AU - Sarkaria, Jann N

PY - 2008/6

Y1 - 2008/6

N2 - Background. 3′-18F-fluoro-3′-deoxy-fluorothymidine ( 18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. Methods. We tested whether 18F-FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. Results. Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18%, whereas placebo increased SUV by 1% (p = .005). One week of cetuximab in SCC1 reduced SUV by 62%, whereas placebo reduced SUV by 16% (p = .005). FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase-1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. Conclusions. 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR-inhibitors early in their treatment course.

AB - Background. 3′-18F-fluoro-3′-deoxy-fluorothymidine ( 18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. Methods. We tested whether 18F-FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. Results. Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18%, whereas placebo increased SUV by 1% (p = .005). One week of cetuximab in SCC1 reduced SUV by 62%, whereas placebo reduced SUV by 16% (p = .005). FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase-1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. Conclusions. 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR-inhibitors early in their treatment course.

KW - Anti-EGFR inhibitor therapy

KW - Cetuximab

KW - Erlotinib

KW - Fluorodeoxythymidine (FLT)

KW - Squamous cell carcinoma xenografts

UR - http://www.scopus.com/inward/record.url?scp=46249132392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249132392&partnerID=8YFLogxK

U2 - 10.1002/hed.20770

DO - 10.1002/hed.20770

M3 - Article

C2 - 18286491

AN - SCOPUS:46249132392

VL - 30

SP - 790

EP - 799

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 6

ER -